Caribou Biosciences opened lower at $0.39, compared with its previous close of $0.39. In the last trading session, the stock traded between $0.37 and $0.39. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Caribou Biosciences is now worth
$ 1.84
Resulting in a loss of
$ 98.16 (98.16%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
33.33%
Hold
66.67%
Sell
0%
Markets Today
Today's Change
$-0.01 (-3.51%)
Day High
$0.39
Day Low
$0.37
Day Open
$0.39
Prev Close
$0.39
Volume
14,21,641
1W Return
-15.09%
1M Return
-23.68%
3M Return
-77.76%
6M Return
-81.43%
1Y Return
-83.17%
Fundamentals
Market Cap ($ Mn)
41
PE Ratio
-
PB Ratio
1.74
PEG Ratio
-
ROE
-82.26%
ROCE
-71.70%
EPS (TTM)
$-0.25
Investment Returns
1 Week
-15.09%
1 Month
-23.68%
3 Months
-77.76%
6 Months
-81.43%
9 Months
-76.29%
Financials
Quarterly
All values in $ Mn
2.4
Mar 25
2.7
Jun 25
2.2
Sep 25
3.9
Dec 25
1.5
Jun 26
1.6
Sep 26
Updates
8Oct
HC Wainwright downgrades Caribou Biosciences to Neutral after Brookline cut
HC Wainwright analyst Robert Burns downgraded Caribou Biosciences from Buy to Neutral. Brookline Capital previously downgraded the stock from Buy to Hold. Shares fell 35.07% to $0.74 after discontinuing two CAR-T programs. Company plans strategic alternatives including potential mergers or acquisitions.
1mo ago
27Aug
67% of car owners report surprise expenses in new Caribou survey
67% of car owners faced at least one unexpected expense in the past year. 75% cannot recall total loan interest, though 70% know their monthly payment. 47% would have made a larger down payment if given the chance. 38% incorrectly believe standard insurance covers GAP protection gaps.
2mo ago
14Aug
Caribou Biosciences Q2 EPS beats estimate, sales miss
Caribou Biosciences reported Q2 2026 results with a net loss of $24.3 million, narrowing from $54.1 million in Q2 2025. EPS of $(0.24) beat the $(0.32) estimate, while sales of $1.499 million missed the $2.279 million forecast. Operating expenses fell to $26.8 million due to cost-cutting measures.
3mo ago
11Jun
Caribou Biosciences reports durable responses in CB-011 trial
Caribou Biosciences reported positive longer follow-up data from the CaMMouflage phase 1 trial of CB-011, showing an 83% complete response rate and 91% MRD negativity in BCMA-naïve patients. A case study of a BCMA-exposed patient also demonstrated an early complete response. Initial dose expansion data is anticipated in H2 2026.
